Valuation: Cognition Therapeutics, Inc.

Market Cap 71M 63.2M 58.51M 53M 99.72M 6.71B 101M 702M 275M 3.52B 266M 261M 11.23B P/E 2026 *
-2.52x
P/E 2027 * -3.39x
Enterprise Value 71M 63.2M 58.51M 53M 99.72M 6.71B 101M 702M 275M 3.52B 266M 261M 11.23B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.71%
Yield 2026 *
-
Yield 2027 * -
1 day+1.74%
1 week-6.87%
Current month-22.23%
1 month-28.21%
3 months-21.29%
6 months-33.34%
Current year-44.70%
1 week 0.71
Extreme 0.713442
0.79
1 month 0.71
Extreme 0.713442
1.03
Current year 0.55
Extreme 0.5501
1.76
1 year 0.55
Extreme 0.5501
1.83
3 years 0.22
Extreme 0.222301
3.83
5 years 0.22
Extreme 0.222301
13
10 years 0.22
Extreme 0.222301
13.8
Manager TitleAgeSince
Chief Executive Officer 66 2020-03-26
Director of Finance/CFO 48 2023-04-30
Chief Tech/Sci/R&D Officer - 2023-12-31
Director TitleAgeSince
Director/Board Member 46 2015-06-30
Director/Board Member 69 2016-08-31
Director/Board Member 66 2019-02-28
Date Insider Type Main position Quantity % Market Cap. Importance
5/1/26 Tax

Chief Financial Officer

-8,567 0.0096%
4/16/26 Buy

Chief Executive Officer

9,175 0.0103%
4/16/26 Buy

Chief Financial Officer

10,000 0.0112%
Change 5-day change 1-year change 3-year change Capi.($)
+1.74%-6.87%-59.20%-42.12% 69.78M
-0.21%-6.36%+49.00%+74.13% 66.34B
-0.22%+10.10%+12.77%+87.32% 52.92B
+0.82%+9.46%+7.75%+73.53% 54.82B
+3.28%+6.12%+30.46%+50.05% 44.09B
+0.51%+10.71%+21.30%+133.92% 43.72B
-1.15%+3.10%+259.71%+594.60% 42.13B
+0.10%+9.96%+17.15%+59.33% 33.96B
-1.30%-3.61%+37.37%+7.16% 26.17B
+0.69%+6.07%+31.89%+26.94% 23.37B
Average +0.43%+3.45%+40.82%+106.49% 38.76B
Weighted average by Cap. +0.32%+4.67%+51.26%+127.74%

Financials

2026 *2027 *
Net sales - -
Net income -27.17M -24.18M -22.39M -20.28M -38.16M -2.57B -38.67M -269M -105M -1.35B -102M -99.77M -4.3B -54.95M -48.91M -45.28M -41.02M -77.18M -5.19B -78.21M -544M -213M -2.73B -206M -202M -8.69B
Net Debt - -
Projected Income Statement - Annual - Cognition Therapeutics, Inc.
Logo Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.
Employees
14
Date Price Change Volume
26-10-21 US$0.7466 +1.74% 293,515
26-10-20 US$0.7338 +0.88% 461,532
26-10-19 US$0.7274 -0.33% 576,304
26-10-16 US$0.7298 -0.38% 431,277
26-10-15 US$0.7326 -5.68% 691,506
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cognition Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.7466USD
Average target price
3.333USD
Spread / Average Target
+346.47%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cognition Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CGTX Stock